Navigation Links
Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/2/2011

ted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Le
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
2. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
3. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
4. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
5. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
6. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
7. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
8. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
9. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
10. Alexza to Present at the MDB Bright Lights Conference 2011
11. Alexza Prices $16.1 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015 The treatment pipeline for ... says  GBI Research . ... Acute Myeloid Leukemia Therapeutics Market to 2020 - forecasts ... moderately from $632.6 million in 2013 to $878.6 million by ... Several drugs to treat AML are expected to ...
(Date:6/3/2015)... SHANGHAI , June 3, 2015 MEDTEC China South ... an extension of MEDTEC China 2015, MEDTEC China South has ... attributes, standing out as a key event for the medical ... After many years of challenges, this year marks the successful return ... 10 years after the event first debuted there in 2005. ...
(Date:6/3/2015)... 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... opioid overdose with intranasal naloxone, has commenced a ... to the United States Food and Drug Administration ... a drug intended to treat opioid overdose.  A ...
Breaking Medicine Technology:Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 2Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 3MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... MUNDELEIN, Ill. , July 20 ... and information systems technology, today announced the addition of ... Sysmex hematology product offering.  The DM1200 enables Sysmex America ... analysis, which improves both the quality of results and ...
... Mich. , July 20 Two southeast Michigan ... in the region.  Delphinus Medical Technologies and Quantum Signal were approved today for ... of Michigan . , , , ... Arbor region continues to be a magnet for growing, high tech companies," ...
Cached Medicine Technology:Sysmex America Begins Distribution of CellaVision® DM1200 2Sysmex America Begins Distribution of CellaVision® DM1200 3Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area 2Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area 3
(Date:6/3/2015)... On Sunday, June 7, 2015, tens of ... their local communities to observe the 28th annual National ... and abroad will hold celebrations on this day to ... challenges of cancer survivorship, and to show the world ... rewarding, and inspiring.,  , National Cancer Survivors Day® is ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
(Date:6/3/2015)... ON (PRWEB) June 03, 2015 On ... a Marketing Authorization (MA), effective immediately, which now permits ... foods that contain oats as ingredients. The MA is ... being developed. All stakeholders should be aware that, unlike ... in the USA, there are restrictions for gluten-free oat ...
(Date:6/3/2015)... Veatch Consulting Services is excited to ... opened for business in April 2006, they have made ... their clients. Each and every year they have worked ... proud to say that they are off to a ... recently added this year is the Customer Review site ...
(Date:6/2/2015)... BALTIMORE, Md. – Ellarea Maria ... about wellness after being diagnosed with lupus. In spite ... lifestyle changes which enhance health, lupus and other autoimmune ... Wellspring for Wellness ,” she offers a holistic approach ... book provides an overview of some autoimmune diseases—especially ...
Breaking Medicine News(10 mins):Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 3Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3
... By Amanda Gardner HealthDay Reporter , THURSDAY, March ... that screening for prostate cancer does not substantially reduce the ... hand, a good many men might receive false-positive results and ... researchers report in the March 31 online issue of the ...
... A potential new experimental diagnostic test able to quickly ... latent TB infection has been developed. If the preliminary ... larger population sample, the new diagnostic system could allow ... re-emerging pathology. The work was performed by ...
... system to perform in vivo RNAi screens for ... hepatocyte proliferation during chronic liver damage.1 Functional ... of the candidate gene by different shRNAs can ... and also increase the regenerative capacity of chronically ...
... new TNM 7 lung cancer staging system seems to ... of lung cancer following surgery, according to a study ... of Thoracic Oncology . Being able to better ... important, especially given the controversies surrounding the use of ...
... target for lung cancer has been discovered by researchers at ... the protein AIMP2 is highly expressed in lung cancer cells ... show lower survival. The study is published on March 31 ... Lung cancer is one of the world,s most common cancers ...
... leading cancer organizations shows rates of death in the United States ... 2003 and 2007. The findings come from the latest Annual Report ... report also finds that the overall rate of new cancer diagnoses ... than 1 percent per year for the same period. Edward ...
Cached Medicine News:Health News:Prostate Cancer Screening Doesn't Cut Death Rates: Study 2Health News:Prostate Cancer Screening Doesn't Cut Death Rates: Study 3Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 2Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 3
... With the GE Innova 2100IQ: See the ... legs. Place interventional devices. Its all enabled ... panel that helps deliver excellent image quality ... Innova family systems installed worldwide, more physicians ...
... provides clinically valuable, device-derived information applicable ... to help specialty physicians discern if ... stable or deteriorating. For example, heart ... Medtronic InSync Sentry™ CRT-D system can ...
... (ALS) is a GH dependent protein which is ... acid peptide with a predicted molecular weight of ... confined to a ~150 KDa GH-dependent ternary protein ... or IGF-II, and this unique acid-labile subunit (ALS) ...
... was first identified in 1980 (1) and has ... of appetite (2). PYY is produced by the ... intake, and is found to decrease appetite. The ... the circulation is PYY3-36, the N-terminal truncated form ...
Medicine Products: